Your browser doesn't support javascript.
Drug supply shortage in Nigeria during COVID-19: efforts and challenges.
Faiva, Edward; Hashim, Hashim Talib; Ramadhan, Mustafa Ahmed; Musa, Shingin Kovona; Bchara, John; Tuama, Yahya Dheyaa; Adebisi, Yusuff Adebayo; Kadhim, Mustafa Hayder; Essar, Mohammad Yasir; Ahmad, Shoaib; Lucero-Prisno, Don Eliseo.
  • Faiva E; Faculty of Pharmaceutical Sciences, Ahmadu Bello University, Zaria, Nigeria.
  • Hashim HT; College of Medicine, University of Baghdad, Baghdad, Iraq.
  • Ramadhan MA; College of Medicine, University of Baghdad, Baghdad, Iraq.
  • Musa SK; Faculty of Pharmaceutical Sciences, Ahmadu Bello University, Zaria, Nigeria.
  • Bchara J; Faculty of Medicine, Tishreen University, Lattakia, Syria. Johnbshara@gmail.com.
  • Tuama YD; College of Medicine, University of Baghdad, Baghdad, Iraq.
  • Adebisi YA; Faculty of Pharmacy, University of Ibadan, Ibadan, Nigeria.
  • Kadhim MH; College of Medicine, University of Kufa, Kufa, Iraq.
  • Essar MY; Medical Research Center, Kateb University, Kabul, Afghanistan.
  • Ahmad S; Kabul University of Medical Sciences, Kabul, Afghanistan.
  • Lucero-Prisno DE; Punjab Medical College, Faisalabad, Pakistan.
J Pharm Policy Pract ; 14(1): 17, 2021 Jan 22.
Article in English | MEDLINE | ID: covidwho-1041899
ABSTRACT
The COVID-19 pandemic has resulted in massive disruptions in global supply chains. Nigeria is particularly vulnerable with respect to pharmaceuticals since there is reduced local production and about 70% of the drug supply is imported creating a huge supply-demand disparity particularly in times like COVID-19. Nigeria is in need of huge quantities of quality-assured health commodities to effectively respond to the pandemic. Significant shortages of other essential medicines and medical products across the country could be imminent. Drug scarcity in Nigeria during the COVID-19 pandemic period is because of several accumulated factors, majorly as a result of global lockdown, decreased manufacturing, unaddressed regulatory affairs, poor access to resources by the population, lack of buffer stocks, security instability, and poor funding of the healthcare system. This situation if left unattended, could cause serious drawbacks to the health of the populace as well as the quality of life of Nigerians amid the COVID-19 Pandemic. Appropriate measures should be directed to ensure ethical processes on drug production, importation, pricing, and distribution to avoid such events during unavoidable scenarios, like the COVID-19 pandemic and other public health emergencies.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Language: English Journal: J Pharm Policy Pract Year: 2021 Document Type: Article Affiliation country: S40545-021-00302-1

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Language: English Journal: J Pharm Policy Pract Year: 2021 Document Type: Article Affiliation country: S40545-021-00302-1